Warning: getimagesize(https://magazine.pharmamkt.net/wp-content/uploads/2020/09/logo-group.jpg): failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /home/luciamun/public_html/magazine/wp-content/plugins/td-cloud-library/shortcodes/header/tdb_header_logo.php on line 792

The largest community of pharma leaders

AppliedVR Receives FDA Breakthrough Device Designation to Treat Pain with Digital Therapeutic

LOS ANGELES–()–AppliedVR, a pioneer advancing the next generation of digital medicine, today announced its EaseVRx product received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for treating treatment-resistant fibromyalgia and chronic intractable lower back pain. EaseVRx is now one of the first virtual reality (VR) digital therapeutics to get breakthrough designation to treat conditions related to chronic pain.

The FDA Breakthrough Device Program helps patients receive more timely access to breakthrough technologies that could provide a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.

AppliedVR achieved this milestone after successfully completing the first randomized controlled trial (RCT), evaluating VR-based therapy for self-management of chronic pain at home. The RCT, which was published in JMIR-FR, found that a self-administered, skills-based VR treatment program for treating chronic pain was feasible, scalable and was effective at improving on multiple chronic pain outcomes – each of which met or exceeded the 30-percent threshold to be clinically meaningful. On average, participants noted:

  • Pain intensity reduced 30 percent;
  • Pain-related activity interference reduced 37 percent;
  • Pain-related mood interference reduced 50 percent;
  • Pain-related sleep interference reduced 40 percent; and
  • Pain-related stress interference reduced 49 percent.

“AppliedVR is the most evidence-backed VR platform on the market, and today’s FDA designation demonstrates that health experts across the spectrum recognize the therapeutic potential of VR as a viable treatment for pain,” said Matthew Stoudt, CEO and co-founder of AppliedVR. “Now, with the COVID-19 pandemic severely disrupting Americans’ ability to get in-person care safely, we’re looking forward to getting EaseVRx into the hands of people suffering from pain. Providers believe in it, patients want it, and payers are coming around to it.”

AppliedVR’s EaseVRx program helps patients learn self-management skills grounded in evidence-based cognitive behavioral therapy (CBT) principles and other behavioral methods. The program was designed by AppliedVR, in partnership with the top pain experts and researchers, to improve self-regulation of cognitive, emotional and physiological responses to stress and pain. AppliedVR has already been shown to be an effective treatment for acute pain in hospital settings.

“Virtual reality is a promising skills-based behavioral medicine that has been shown to have high patient engagement and satisfaction,” said Dr. Beth Darnall1, AppliedVR’s chief science advisor. “However, chronic pain patients to date have had very limited access to it, so we’re excited to continue working with the FDA to develop our platform and get it into the market faster.”

Lower back pain is one of the most common chronic conditions that people face worldwide and represents one of the top reasons why people miss work. Additionally, it’s an extremely costly problem for insurers, especially as they look to cut costs related to back surgery. Recent research indicated that, when combined with neck pain, lower back pain costs nearly $77 billion to private insurance, $45 billion to public insurance, and $12 billion in out-of-pocket costs for patients.

Chronic pain more broadly also is a difficult and costly problem that has contributed to many other major health problems in the U.S., including the opioid epidemic. A previous Johns Hopkins study in the Journal of Pain found that chronic pain can cumulatively cost as high as $635 billion a year — more than the annual costs of cancer, heart disease and diabetes — and lower back pain has been one of the most common reasons for prescribing opioids. Cognitive behavioral therapies like VR are now seen by many providers as an effective alternative or complement to pharmacological interventions that can support their larger treatment tool belts.

“Since 1980, the American Chronic Pain Association has advocated a multidisciplinary approach to pain management—using a combination of medical and behavioral techniques to address pain,” said Penny Cowan, founder and CEO of the American Chronic Pain Association. “Virtual reality has the potential to be an important resource in this approach, helping people with pain to think differently about their conditions and learn strategies to reduce suffering and improve quality of life.”

AppliedVR is currently engaged in many other trials, including feasibility studies with multiple well-known payers and with the University of California at San Francisco (UCSF) to study how digital therapeutic platforms, including virtual and augmented reality, can be used to improve care access for underserved populations. AppliedVR also is advancing two clinical trials with Geisinger and Cleveland Clinic to study VR as an opioid-sparing tool for acute and chronic pain – specifically the company’s RelieVRx and EaseVRx platforms. The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), recently awarded $2.9 million grants to fund the trials.

About AppliedVR

AppliedVR is pioneering the next generation of digital medicines to deliver safe and effective virtual reality therapeutics (VRx) that address unmet needs and improve clinical outcomes for patients with serious health conditions. Its evidence-based, non-invasive treatments immerse and engage patients to help drive measurable clinical outcomes. As the most widely used and deeply researched therapeutic VR platform, AppliedVR is the first company to make VR therapeutics widely available in clinical care, having immersed more than 60,000 patients in more than 200 hospitals. AppliedVR has established world-class research and commercial partnerships and continues to build the infrastructure to accelerate the mass adoption of VRx. To learn more about AppliedVR, Inc., visit https://appliedvr.io/.

______________________________________________________________

1 Beth Darnall, PhD also is associate professor at Stanford University School of Medicine and is Director of the Stanford Pain Relief Innovations Lab. She leads NIH and PCORI-funded large clinical trials involving behavioral treatments for acute and chronic pain.

Source

0FansLike
0FollowersFollow
0FollowersFollow
0FollowersFollow

Recent Articles

Asana BioSciences to Present Positive Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema in the Late-Breaking...

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences’ Oral Gusacitinib (ASN002) demonstrates rapid and significant...

Aptinyx Announces Proposed Public Offering of Common Stock

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing...

Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging...

AppliedVR Receives FDA Breakthrough Device Designation to Treat Pain with Digital Therapeutic

LOS ANGELES--(BUSINESS WIRE)-- #chronicpain--AppliedVR, a pioneer advancing the next generation of...

After Meeting with FDA, Guided Therapeutics to Start Study in Support of its Application for FDA Approval

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- #FDA--After Meeting with FDA, Guided Therapeutics to...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.